|
US4043996A
(en)
|
1975-01-27 |
1977-08-23 |
Swift & Company |
Gelatin manufacture-peroxide liquefaction process
|
|
GB1557005A
(en)
|
1975-07-11 |
1979-12-05 |
Novo Industri As |
Gelatine extraction
|
|
US4176117A
(en)
|
1977-03-11 |
1979-11-27 |
Leon Oudem |
Process for obtaining gelatin
|
|
US4232425A
(en)
|
1980-01-15 |
1980-11-11 |
Darling & Company |
Method of producing stabilized bone
|
|
ZA816771B
(en)
|
1980-10-07 |
1982-10-27 |
Lensfield Prod Ltd |
Protein production
|
|
US4374063A
(en)
|
1981-09-28 |
1983-02-15 |
General Foods Corporation |
Process for the preparation and purification of gelatin and pyrogen-free gelatin so prepared
|
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
|
US4402873A
(en)
|
1982-09-23 |
1983-09-06 |
Sugardale Foods Incorporated |
Extraction of protein from pork bones
|
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
|
DE3726963A1
(de)
|
1987-08-13 |
1989-02-23 |
Stoess & Co Gelatine |
Kaltwasserloesliche, instantisierte gelatine und verfahren zur herstellung derselben
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
FR2625412B1
(fr)
|
1987-12-30 |
1990-06-29 |
Mero Rousselot Satia |
Procede continu d'obtention de gelatine a partir de poudre d'os et gelatine obtenue
|
|
IL87344A
(en)
|
1988-08-04 |
1992-03-29 |
Univ Bar Ilan |
Process for the production of gelatin from fish skins
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
DE69132510T2
(de)
|
1990-11-08 |
2001-05-03 |
Hybridon, Inc. |
Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
|
|
US5210182A
(en)
|
1992-02-12 |
1993-05-11 |
Kraft General Foods, Inc. |
Extraction process for gelatin
|
|
US5288408A
(en)
|
1992-10-26 |
1994-02-22 |
Chemical Industry Consultants, Inc. |
Method of gelatin recovery and purification from encapsulation processes
|
|
WO1994014226A1
(en)
|
1992-12-14 |
1994-06-23 |
Honeywell Inc. |
Motor system with individually controlled redundant windings
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
EP0804456B1
(en)
|
1994-10-06 |
2002-08-21 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid conjugates
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5684142A
(en)
|
1995-06-07 |
1997-11-04 |
Oncor, Inc. |
Modified nucleotides for nucleic acid labeling
|
|
US6090915A
(en)
|
1996-10-18 |
2000-07-18 |
Hormel Foods Corporation |
Collagen or gelatin crumble composition and uses
|
|
US5851579A
(en)
|
1996-10-28 |
1998-12-22 |
Eastman Chemical Company |
Aqueous enteric coating compositions
|
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
US5770716A
(en)
|
1997-04-10 |
1998-06-23 |
The Perkin-Elmer Corporation |
Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
|
|
ES2210761T3
(es)
|
1997-05-21 |
2004-07-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
|
|
EP1015469B2
(en)
|
1997-09-12 |
2015-11-18 |
Exiqon A/S |
Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
GB9807331D0
(en)
|
1998-04-07 |
1998-06-03 |
Cerestar Holding Bv |
Gelatin replacement by wheat fiber gel and starch
|
|
US6096875A
(en)
|
1998-05-29 |
2000-08-01 |
The Perlein-Elmer Corporation |
Nucleotide compounds including a rigid linker
|
|
US6335432B1
(en)
|
1998-08-07 |
2002-01-01 |
Bio-Red Laboratories, Inc. |
Structural analogs of amine bases and nucleosides
|
|
US6335437B1
(en)
|
1998-09-07 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Methods for the preparation of conjugated oligomers
|
|
AU3357800A
(en)
|
1999-02-05 |
2000-08-25 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
EP1535625B1
(en)
|
1999-04-05 |
2014-01-08 |
Novartis AG |
Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
|
|
NZ534409A
(en)
|
1999-04-05 |
2006-03-31 |
Emisphere Tech Inc |
Disodium salts, monohydrates, and ethanol solvates for delivering active agents
|
|
ATE356824T1
(de)
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US6375981B1
(en)
|
2000-06-01 |
2002-04-23 |
A. E. Staley Manufacturing Co. |
Modified starch as a replacement for gelatin in soft gel films and capsules
|
|
AR040737A1
(es)
|
2002-08-01 |
2005-04-20 |
Novartis Ag |
Administracion oral de calcitonina
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
EP2284269B1
(en)
|
2002-11-18 |
2017-08-09 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
|
MXPA06000446A
(es)
|
2003-07-11 |
2006-04-07 |
Novartis Ag |
Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
|
|
DK1661905T3
(da)
|
2003-08-28 |
2012-07-23 |
Takeshi Imanishi |
Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
|
|
WO2007031091A2
(en)
*
|
2005-09-15 |
2007-03-22 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of p21 ras expression
|
|
PE20070548A1
(es)
|
2005-09-19 |
2007-07-12 |
Emisphere Tech Inc |
Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
|
|
DE602007009487D1
(de)
|
2006-01-27 |
2010-11-11 |
Isis Pharmaceutical Inc |
6-modifizierte bicyclische nukleinsäureanaloga
|
|
EP2505646A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of CRP
|
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
EP2059260B1
(en)
*
|
2006-08-31 |
2013-06-19 |
Novartis AG |
Pharmaceutical compositions comprising hGH for oral delivery
|
|
MX2009002121A
(es)
|
2006-09-07 |
2009-05-20 |
Hoffmann La Roche |
Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
DK2170917T3
(da)
|
2007-05-30 |
2012-10-08 |
Isis Pharmaceuticals Inc |
N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
|
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
AU2008272918B2
(en)
|
2007-07-05 |
2012-09-13 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
WO2009019307A2
(en)
|
2007-08-09 |
2009-02-12 |
Novartis Ag |
Oral calcitonin compositions and applications thereof
|
|
DK2205737T3
(da)
|
2007-10-04 |
2013-05-21 |
Santaris Pharma As |
Mikromirer
|
|
WO2009067647A1
(en)
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
|
EP2265627A2
(en)
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
US9290534B2
(en)
|
2008-04-04 |
2016-03-22 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
WO2010142805A1
(en)
|
2009-06-12 |
2010-12-16 |
Santaris Pharma A/S |
New potent anti apob antisense compounds
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
RU2013117288A
(ru)
|
2010-12-17 |
2015-01-27 |
Эрроухэд Рисерч Корпорейшн |
СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
|
|
US9402147B2
(en)
|
2011-07-11 |
2016-07-26 |
National Taiwan University |
Enhanced paging mechanism for machine type communication
|
|
US9796974B2
(en)
|
2011-11-18 |
2017-10-24 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
|
MX375442B
(es)
*
|
2012-09-21 |
2025-03-06 |
Intensity Therapeutics Inc |
Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
|
|
CA2894174A1
(en)
|
2012-12-06 |
2014-06-12 |
Regado Biosciences Inc. |
Oligonucleotide formulation
|
|
US20140323543A1
(en)
|
2013-04-25 |
2014-10-30 |
Jeremy Richard Graff |
Treatment of Prostate Cancer with eIF4E Antisense Compounds
|
|
MX367083B
(es)
|
2013-06-27 |
2019-08-05 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
|
|
EP3151839A4
(en)
*
|
2014-06-06 |
2018-02-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
CN104095828A
(zh)
*
|
2014-07-29 |
2014-10-15 |
中国药科大学 |
一种降钙素口服肠溶组合物及其制备方法
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
WO2018049285A1
(en)
|
2016-09-09 |
2018-03-15 |
Fred Hutchinson Cancer Research Center |
Stable peptides and methods of use thereof
|
|
WO2018098328A1
(en)
|
2016-11-23 |
2018-05-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rna agents with reduced off-target effect
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
CA3114396A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
WO2020236600A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
MX2023012437A
(es)
|
2021-04-22 |
2023-11-07 |
Civi Biopharma Inc |
Administracion oral de oligonucleotidos.
|